TABLE 1.
Demographic and Disease Characteristics of 304 Patients in Whom Androgen Deprivation Therapy Failed
| Clinical characteristic | Value |
|---|---|
| Race | |
| White | 301 (99) |
| Others | 3 (1) |
| Age, median (IQR) (y) | 72 (47-91) |
| PSA at the time of ADT failure, median (range) (ng/mL) | 11.5 (4-46) |
| Clinical T stage at first diagnosis | |
| T1 | 18 (6) |
| T2 | 127 (42) |
| T3+4 | 16 (5) |
| T4 | 41 (13) |
| TX (unverifiable) | 102 (34) |
| N0 | 37 (12) |
| N1 | 4 (1) |
| NX | 263 (87) |
| Patients with no metastatic disease at diagnosis (M0) | 279 (92) |
| Patients with metastatic disease at diagnosis (M1) | 23 (8) |
| Mx (unverifiable) | 2 (1) |
| Time from diagnosis to ADT initiation (y) | |
| For initially nonmetastatic patients (M0), median (IQR) | 1.5 years (19 days to 5 years) |
| For initially metastatic patients (M1), median (IQR) | 16 days (0-31 days) |
| Biopsy Gleason score at initial diagnosis | |
| <6 | 65 (21) |
| 7 | 90 (30) |
| >8 | 121 (40) |
| Unknown | 28 (9) |
| Definitive local therapy | |
| None | 85 (28) |
| Radical prostatectomy | 131 (43) |
| Radiation therapy | 88 (29) |
| Type of ADT | |
| LHRH analogue | 210 (69) |
| Orchiectomy | 94 (31) |
Data are presented as No. (percentage) of patients unless indicated otherwise. ADT = androgen deprivation therapy; IQR = interquartile range; LHRH = luteinizing hormone-releasing hormone; PSA = prostate-specific antigen.